A combination of imatinib mesylate with a PIM inhibitor can increase CML-SCs apoptosis, decrease colony formation, and prolong survival of the CML mouse model, without obvious side effects on HSCs [114]. Here, PIM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.